Among 140 patients who underwent colonoscopy or a colonoscopy-plus-EGD, "inadequate bowel preparation" (stool retained in the bowel) was observed in 21.3% of those who were taking a GLP-1 medicine ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...

Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's ...

The new Lemme GLP-1 Daily Capsules are being called an "Ozempic alternative." But do they really work — and if so, at what ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Read here for an analysis of LifeVantage's (LFVN) stock surge post GLP-1 trial, cautioning on pricing, retention, and ...

The quest for effective and safe weight loss solutions has long been a focus of medical research. In recent years, a novel ...

The demand for weight loss medications are on the rise, and now, “natural” GLP-1s are being marketed to help you lose weight.

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...

Results of the human clinical trial will be shared with LifeVantage Consultants at Market Connect in Kansas City, October ...